Top

International Journal of Clinical Oncology

Published in:

01-06-2015 | Original Article

Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan

Authors: Hideki Tokunaga, Toru Nakanishi, Takashi Iwata, Daisuke Aoki, Toshiaki Saito, Satoru Nagase, Fumiaki Takahashi, Nobuo Yaegashi, Yoh Watanabe

Published in: International Journal of Clinical Oncology | Issue 3/2015

Abstract

Background

Predictive factors of the efficacy of chemotherapy for Japanese patients with recurrent cervical cancer who have been previously treated with concurrent chemoradiotherapy (CCRT) are currently unknown, and hence we aimed to investigate this.

Methods

We retrospectively studied the prognostic outcomes of patients with recurrent cervical cancer treated with CCRT between 2002 and 2010 at four medical facilities.

Results

A total of 64 patients were included in this study. Forty-two patients received definitive CCRT and 22 patients received postoperative adjuvant CCRT, with 55 receiving platinum-based combination chemotherapy and nine receiving single-agent chemotherapy. The overall response rate (ORR) was 12.5 %, with one complete response. The median survival period was 12 months. The ORR and overall survival rate did not differ significantly according to recurrence site, post-CCRT interval, or chemotherapy regimen.

Conclusion

None of the factors analyzed in this study were identified as positive predictive factors for the efficacy of chemotherapy in patients with recurrent cervical cancer after CCRT. Based on the results of previous studies, in order to improve long-term prognosis in recurrent cases, adjuvant chemotherapy should be considered as a potential treatment option for selected patients, especially as postoperative adjuvant therapy.

Peters WA 3rd, Liu PY, Barrett RJ et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613PubMed

Rose PG (2000) Chemoradiotherapy: the new standard care for invasive cervical cancer. Drugs 60:1239–1244PubMedCrossRef

Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143PubMedCrossRef

Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153PubMedCrossRef

Whitney CW, Sause W, Bundy BN et al (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 17:1339–1348PubMed

Green JA, Kirwan JM, Tierney JF et al (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358:781–786PubMedCrossRef

Lukka H, Hirte H, Fyles A et al (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis. Clin Oncol 14:203–212CrossRef

(2014) National comprehensive cancer network guidelines for treatment of cancer. http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Retrieved March 13, 2014

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

10.

Omura GA, Blessing JA, Vaccarello L et al (1997) Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15:165–171PubMed

11.

Bloss JD, Blessing JA, Behrens BC et al (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20:1832–1837PubMedCrossRef

12.

Moore DH, Blessing JA, McQuellon RP et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113–3119PubMedCrossRef

13.

Long HJ 3rd, Bundy BN, Grendys EC Jr et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633PubMedCrossRef

14.

Teshima T, Inoue T, Ikeda H et al (1993) High-dose rate and low-dose rate intracavitary radiation therapy for cancer of the uterine cervix. Final results of Osaka University Hospital. Cancer 72:2409–2414PubMedCrossRef

15.

Watanabe Y, Nakai H, Shimaoka M et al (2006) Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. Int J Clin Oncol 11:309–313PubMedCrossRef

16.

Ikushima H, Osaki K, Furutani S et al (2006) Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiat Med 24:115–121PubMedCrossRef

17.

Toita T, Kitagawa R, Hamano T et al (2012) Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066). Int J Gynecol Cancer 22:1420–1426PubMedCrossRef

18.

Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655PubMedCentralPubMedCrossRef

19.

Moore DH, Tian C, Monk BJ et al (2010) Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 116:44–49PubMedCrossRef

20.

Shimada M, Nishimura R, Hatae M et al (2013) Comparison of adjuvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/TGCU Intergroup surveillance. Eur J Gynaecol Oncol 34:425–428PubMed

21.

Li S, Hu T, Chen Y et al (2013) Adjuvant chemotherapy, a valuable alternative option in selected patietns with cervical cancer. PLoS One. doi:10.1371/journal.pone.0073837

22.

Lee TY, Jeung YJ, Lee CJ et al (2013) Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer. Obstet Gynecol Sci 56:15–21PubMedCentralPubMedCrossRef

23.

Takeshima N, Umayahara K, Fujiwara K et al (2006) Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Gynecol Oncol 103:618–622PubMedCrossRef

24.

Pignata S, Frezza P, Tramontana S et al (2000) Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol 11:455–459PubMedCrossRef

25.

Rao GC, Rogers P, Drake RD et al (2005) Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gyncol Oncol 96:168–172CrossRef

26.

Sehouli J, Runnebaum IB, Fotopoulou C et al (2012) A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol 23:2259–2264PubMedCrossRef

27.

Tewari KS, Sill MW, Long HJ III et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743PubMedCentralPubMedCrossRef

28.

Schefter TE, Winter K, Kwon JS et al (2011) A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys 83:1179–1184CrossRef

Title: Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan
Authors: Hideki Tokunaga
Toru Nakanishi
Takashi Iwata
Daisuke Aoki
Toshiaki Saito
Satoru Nagase
Fumiaki Takahashi
Nobuo Yaegashi
Yoh Watanabe
Publication date: 01-06-2015
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0728-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Molecular pathogenesis of multiple myeloma

Initial experience of combined use of photodynamic diagnosis and narrow band imaging for detection of flat urothelial lesion

Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up

Current therapeutic strategies for multiple myeloma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer